| Patient | Booker T. Washington |
|---|---|
| Date of birth | 1967-04-05 |
| Identifiers | MRN HR-NI017-SYN; SSN (made up) 000-17-2284 |
| Document date | 2026-05-11 |
| Author | Lorraine Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week blood pressure and kidney safety check. [S]
Mr. Washington returns one week after starting amlodipine and losartan for severe hypertension with stage G3b chronic kidney disease. His home readings, taken twice daily, have fallen from above 200 systolic to the 160s and 170s over 100s. He has had one mild frontal headache this week, fewer than before, and no chest pain, breathlessness, weakness, confusion, or sudden change in vision. His palpitations are less frequent. He has had no lightheadedness on standing and no ankle swelling, and he takes both medicines every morning. His reading vision is still blurred and he still gets up twice a night to urinate. He asks how to keep to the plan on travel days. His nephrology consultation, kidney ultrasound, and echocardiogram were done today. [S]
| Element | Detail |
|---|---|
| Home blood pressure | 160s to 170s over 100s, down from above 200 systolic |
| Symptoms | One mild headache this week; palpitations less frequent |
| Warning signs | No chest pain, breathlessness, weakness, confusion, or sudden vision change |
| Medication tolerance | No lightheadedness or ankle swelling |
| Adherence | Every dose taken |
| Patient goal | A plan that works on travel days |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by midafternoon; weight stable |
| Eyes | Positive | Reading vision blurred, unchanged; no sudden loss of vision |
| Cardiovascular | Positive | Occasional palpitations, less frequent; no chest pain or ankle swelling |
| Respiratory | Negative | No breathlessness |
| Genitourinary | Positive | Up twice a night to urinate; no dysuria or blood in the urine |
| Neurological | Positive | One mild frontal headache; no weakness, numbness, confusion, or lightheadedness on standing |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-11 | Body height | 170 | cm | S |
| 2026-05-11 | Body weight | 71 | kg | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 2026-05-11 | Systolic blood pressure | 172 | mm[Hg] | S |
| 2026-05-11 | Diastolic blood pressure | 104 | mm[Hg] | S |
| 2026-05-11 | Heart rate | 82 | /min | S |
| 2026-05-11 | Respiratory rate | 16 | /min | S |
| 2026-05-11 | Body temperature | 36.7 | Cel | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-11 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-11 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-05-11 | Urea nitrogen [Mass/volume] in Serum or Plasma | 36 | mg/dL | 6-24 mg/dL | High | S |
| 2026-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 2.2 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 34 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-05-11 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-11 | Left ventricular Ejection fraction | 60 | % | 50-70% | Normal | S |
Vital signs recorded on 2026-05-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, articulate, and in no distress |
| Blood pressure | 172/104 mmHg, the average of two seated readings after five minutes' rest with a validated cuff |
| Eyes | Undilated fundi show the arteriolar narrowing seen last week; no hemorrhages or papilledema |
| Heart | Regular rhythm, rate 82; S4; no murmur |
| Lungs | Clear |
| Extremities | No edema |
| Neurological | Fluent speech; no focal deficit |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150 | active | confirmed | I12.9 | S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R. |
| Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis | active | confirmed | N18.32 | S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease. |
| Hypertensive retinopathy, both eyes, without papilledema | active | confirmed | H35.033 | S — Synthetic funduscopic finding that echoes the documented failing vision. |
| Mild anemia of chronic kidney disease, iron replete; monitor | active | confirmed | D63.1 | S — Synthetic finding from the baseline hemoglobin and iron studies. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine (basic metabolic panel) | 2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR draw | Completed today | One week after starting losartan, earlier than the CMID window because of severe hypertension and eGFR 36; the care plan uses one to four weeks. Potassium 4.6, creatinine 2.2 mg/dL (up 5 percent), eGFR 34, bicarbonate 22 |
| Laboratory | Potassium and creatinine after today's changes | 2 to 4 weeks after titrating losartan or starting dapagliflozin | Due | Losartan doubles and dapagliflozin starts today; drawn at the three-week check |
| Laboratory | eGFR and urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Up to date | Urine albumin-creatinine ratio 820 mg/g at diagnosis; repeat once the regimen is complete |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months in G3b | Up to date | Calcium 9.1, phosphate 4.2, PTH 92 pg/mL (mildly raised) at diagnosis; next at the six-month review |
| Laboratory | 25-hydroxyvitamin D | Once at baseline | Due | Not drawn at diagnosis; PTH is mildly raised. To be drawn with the six-month calcium, phosphate, and PTH |
| Laboratory | Urinalysis with microscopy | At diagnosis, then with a change in status | Deferred | Not on file from the diagnostic workup, a deviation from the protocol. It screens for blood or casts that would point away from hypertensive nephrosclerosis. Today's ultrasound and the history fit hypertensive kidney disease, so no harm is evident. Corrective action: obtain it if albuminuria does not fall on treatment or kidney function changes unexpectedly |
| Laboratory | Hemoglobin | At least yearly in G3 | Up to date | 12.6 g/dL at diagnosis; iron studies show iron-replete anemia of chronic kidney disease |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5; before referral decisions | Deferred | Not calculated before the nephrology referral, a deviation from the protocol. The referral stood on other criteria (eGFR below 60 with severely increased albuminuria), so no harm resulted. Corrective action: calculate at the six-month review, once eGFR has settled on full therapy |
| Referral | Nephrology consultation | eGFR below 60 with persistent A3 albuminuria | Completed today | Seen today; agrees with the plan |
| Imaging | Kidney ultrasound | At diagnosis when chronicity or obstruction is in question; not for routine surveillance | Completed today | Kidneys 9.4 and 9.6 cm and echogenic, without hydronephrosis: chronic kidney disease, not obstruction |
| Imaging | Transthoracic echocardiogram | At diagnosis for stage 2 hypertension or suspected left ventricular hypertrophy | Completed today | Concentric left ventricular hypertrophy; ejection fraction 60 percent |
| Imaging | 12-lead ECG | At diagnosis | Up to date | Sinus rhythm with left ventricular hypertrophy by voltage last week |
| Examination | Funduscopic examination | Yearly in chronic hypertension | Up to date | Dilated examination last week; next in a year |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 172/104 mmHg |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 71 kg, BMI 24.6; S4 without murmur |
| Laboratory | HbA1c and TSH | HbA1c yearly; TSH at diagnosis | Up to date | HbA1c 5.4 percent and TSH 1.8 at diagnosis |
| Survey | PHQ-9 | Yearly in hypertension | Up to date | Score 4 at diagnosis |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs or over-the-counter products; doses checked for eGFR 34 |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Completed today | PCV20 and hepatitis B vaccine dose 1 given today; influenza vaccine given last fall |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Home log reviewed; travel plan agreed |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)
Follow-up: Three-week check with potassium and creatinine after the losartan increase and dapagliflozin start. Next scheduled visit 2026-06-01: three-week check after losartan titration and dapagliflozin start. [S]